| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
As a chemical linker, Amino-PEG6-acid itself does not have a biological target. Its utility lies in its ability to serve as a hydrophilic, flexible spacer in the synthesis of bifunctional molecules such as PROTACs. In PROTAC design, one ligand binds to the target protein and another ligand binds to an E3 ubiquitin ligase; these two ligands are connected by a linker. The hydrophilic PEG spacer enhances the aqueous solubility and flexibility of the resulting PROTAC, which are critical for optimal ternary complex formation and target protein degradation.
|
|---|---|
| ln Vitro |
An ADC cytotoxin is connected to an antibody by use of an ADC linker to form an ADC.
As a chemical linker, Amino-PEG6-acid does not exhibit intrinsic biological activity and therefore does not have conventional in vitro activity. Its in vitro utility is demonstrated in the synthesis and evaluation of PROTACs, where it is used to connect a target-binding ligand to an E3 ligase-binding ligand. The efficiency of PROTAC synthesis using this linker is typically assessed by HPLC and mass spectrometry. The linker's role is to ensure optimal spacing and flexibility for ternary complex formation. |
| ln Vivo |
As a chemical linker, Amino-PEG6-acid does not possess intrinsic biological activity and therefore is not evaluated in conventional in vivo efficacy models. Its in vivo relevance is demonstrated through the biological activity of the PROTAC degraders it helps to form. The PEG component of the linker can contribute to improved pharmacokinetic properties of the PROTAC, including enhanced solubility and reduced immunogenicity, which are beneficial for in vivo applications.
|
| Enzyme Assay |
In a typical non-cellular conjugation experiment, Amino-PEG6-acid is dissolved in an appropriate solvent such as DMSO or DMF. The carboxylic acid group is activated using a coupling reagent such as HATU, HOBt, or EDC in the presence of a base. The activated ester is then reacted with an amine-containing molecule to form an amide bond. Alternatively, the amino group of the linker can be reacted with a carboxylic acid-containing molecule. The reaction is carried out at room temperature. The product is purified by column chromatography or preparative HPLC and characterized by NMR and mass spectrometry.
|
| Cell Assay |
Since Amino-PEG6-acid is a chemical linker rather than a drug substance, standard in vitro cell-based assays are not directly applicable. However, the cellular activity of the PROTAC degraders that incorporate this linker can be assessed in relevant cell lines. A PROTAC containing this linker can be evaluated for its ability to degrade a target protein in cancer cells via Western blot analysis. Cell viability assays such as MTT or CellTiter-Glo can be used to assess the functional consequences of target protein degradation.
|
| Animal Protocol |
As a chemical linker, Amino-PEG6-acid is not administered to animals as a therapeutic agent. In vivo studies are conducted with the final PROTAC conjugates that incorporate this linker. These studies typically involve xenograft mouse models for efficacy evaluation, where tumor-bearing mice are treated with the PROTAC, and tumor growth inhibition is measured. Pharmacokinetic studies may also be performed to assess the impact of the PEG linker on circulation half-life and biodistribution.
|
| ADME/Pharmacokinetics |
As a chemical linker, Amino-PEG6-acid is not a therapeutic agent and therefore does not have a pharmacokinetic profile of its own. The pharmacokinetic properties of the linker are relevant only in the context of the final PROTAC conjugate. The hydrophilic PEG spacer can contribute to favorable PK properties of the conjugate, such as increased aqueous solubility and reduced aggregation. The overall PK profile is determined by the combined properties of the ligands and the linker.
|
| Toxicity/Toxicokinetics |
Amino-PEG6-acid is a research-use chemical and is not intended for human therapeutic use. As a PEG-based linker, it is generally considered to have low inherent toxicity, although appropriate safety precautions should be taken. The potential toxicity of the final PROTAC conjugates incorporating this linker is determined by the specific ligands used.
|
| References | |
| Additional Infomation |
Amino-PEG6-acid is a heterobifunctional PEG linker used in PROTAC development and bioconjugation. The compound contains an amino group and a carboxylic acid, enabling orthogonal conjugation strategies. The 6-unit PEG spacer provides flexibility and solubility for the resulting conjugates. The compound is commonly used in research settings for the development of targeted protein degradation therapies and is not an approved drug.
|
| Molecular Formula |
C15H31NO8
|
|---|---|
| Molecular Weight |
353.4085
|
| Exact Mass |
353.205
|
| CAS # |
905954-28-1
|
| PubChem CID |
51035062
|
| Appearance |
White to light yellow solid powder
|
| LogP |
0.219
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
20
|
| Heavy Atom Count |
24
|
| Complexity |
268
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
PVRGRRPCHFTMMD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H31NO8/c16-2-4-20-6-8-22-10-12-24-14-13-23-11-9-21-7-5-19-3-1-15(17)18/h1-14,16H2,(H,17,18)
|
| Chemical Name |
3-[2-[2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8296 mL | 14.1479 mL | 28.2957 mL | |
| 5 mM | 0.5659 mL | 2.8296 mL | 5.6591 mL | |
| 10 mM | 0.2830 mL | 1.4148 mL | 2.8296 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT01910025 | Completed | Drug: ADI-PEG 20 | Non-Hodgkin's Lymphoma | Polaris Group | 2013-12-06 | Phase 2 |
| NCT01910012 | Completed | Drug: ADI-PEG 20 | Acute Myeloid Leukemia | Polaris Group | 2015-01-06 | Phase 2 |
| NCT01665183 | Completed | Drug: ADI-PEG 20 | Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors |
Polaris Group | 2012-09 | Phase 1 |
| NCT00450372 | Completed | Biological: ADI-PEG-20 Other: Pharmacology Studies |
Melanoma (Skin) | University of Miami | 2004-06 | Phase 2 |
| NCT02006030 | Completed | Drug: ADI-PEG 20 Drug: Transarterial chemoembolization |
Unresectable Hepatocellular Carcinoma | Polaris Group | 2014-10-15 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
